Iteos Home

Press Releases

Home / Investors / iTeos Therapeutics Announces Opening of New Corporate Headquarters

Press Release Details

iTeos Therapeutics Announces Opening of New Corporate Headquarters

November 28, 2016
PDF Version

Gosselies, Belgium – November 28, 2016 – iTeos, a biotechnology company applying its expertise in translational tumor immunology to the development of novel cancer immunotherapies, announced today that it has completed the relocation of its 39 employees into a newly rebuilt, 1,500 square meter (16,200 square foot) corporate headquarters which now houses iTeos’ offices and laboratories. The new facilities are in the EOLE building located at Rue des Frères Wright 29, 6041 Gosselies, Belgium.

 

"These facilities give us the space to not only expand our new cancer target research programs and drug development capacities, but also grow our highly-skilled team. These laboratories include dedicated cell culture rooms, and labs dedicated to flow cytometry and biomarker analysis and will enable us to rapidly advance our drug candidates into clinical development," stated Michel Detheux, iTeos’ chief executive officer.

 

Christophe Quéva, chief scientific officer, commented "The building of a custom designed R&D facility demonstrates our commitment to our cancer immunology research programs and will enable us to recruit additional qualified scientists needed in both our drug discovery and development.”

 

About iTeos Therapeutics SA

Based in Gosselies, Belgium, iTeos, a spin-off of Ludwig Cancer Research (LICR) and de Duve Institute (UCL), expands the benefits of immunotherapy to cancer patients. The company develops a proprietary pipeline targeting A2A, immune checkpoints and non-immunogenic tumors, and has licensed its IDO1 program, now in Phase 1, to Pfizer. iTeos’ competitive edge is in the combination of expertise in drug discovery and translational tumor immunology. The company uses a unique platform to identify rationale combination of immunotherapies and novel targets. The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development).

For investors

scientist picking up a petri dish

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.

Driven by a culture of scientific innovation, collaboration and excellence, together we discover and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.